The estimated Net Worth of Richard A Young is at least $1.52 Milhão dollars as of 28 June 2024. Richard Young owns over 34,837 units of Syros Pharmaceuticals stock worth over $12,880 and over the last 8 years he sold SYRS stock worth over $1,298,023. In addition, he makes $209,332 as Director at Syros Pharmaceuticals.
Richard has made over 16 trades of the Syros Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 34,837 units of SYRS stock worth $178,365 on 28 June 2024.
The largest trade he's ever made was selling 34,837 units of Syros Pharmaceuticals stock on 28 June 2024 worth over $178,365. On average, Richard trades about 5,479 units every 97 days since 2016. As of 28 June 2024 he still owns at least 8,000 units of Syros Pharmaceuticals stock.
You can see the complete history of Richard Young stock trades at the bottom of the page.
Dr. Richard A. Young Ph.D. serves as Director of the Company. He is also one of our scientific co-founders and a member of our scientific advisory board. He has been a member of the Whitehead Institute and professor of Biology at the Massachusetts Institute of Technology since 1984. In May 2012, he was elected into the National Academy of Sciences. Dr. Young has served as an advisor to Science magazine and the World Health Organization. Dr. Young previously served as a director of Enzon Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Young received his Ph.D. in molecular biophysics and biochemistry from Yale University. Young is qualified to serve on our board of directors because of his scientific expertise and his role as one of our scientific co-founders.
As the Director of Syros Pharmaceuticals, the total compensation of Richard Young at Syros Pharmaceuticals is $209,332. There are 9 executives at Syros Pharmaceuticals getting paid more, with Nancy Simonian having the highest compensation of $3,614,020.
Richard Young is 66, he's been the Director of Syros Pharmaceuticals since 2011. There are 4 older and 15 younger executives at Syros Pharmaceuticals. The oldest executive at Syros Pharmaceuticals Inc. is Phillip Sharp, 75, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA, 02140.
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju, eStephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Syros Pharmaceuticals executives and other stock owners filed with the SEC include: